Whitehawk Therapeutics, Inc.: Dellora Investments LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Dellora Investments LP disclosed a stake exceeding 5% in Whitehawk Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0001943462-26-000010). The passive-investor disclosure signals a significant new institutional holder in the clinical-stage biotech. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments or 13D filings that could indicate activist intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Dellora Investments LP, Whitehawk Therapeutics, Inc.